Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics and West Virginia University’s ...

HOPE is evaluating Cognito’s investigative non-invasive neuroprotective therapy to better preserve cognition and function in patients with Alzheimer’s. The study is the largest ever medical device ...

Amazon Web Services (AWS) has announced updates to Amazon Cognito, its identity and access management service for Web and mobile applications. The service allows developers to secure ...

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as ...

Cognito Forms is a game-changer, automating administrative work and streamlining business processes. Its powerful data collection and user-friendly interface empower global innovators. With both free ...

Embark on an exciting journey to uncover the wonders of cell division as we explore mitosis and meiosis. In this captivating explanation, we'll delve into how cells divide and pass on genetic ...

A new production company is on the mission to bring weird science to life through story. Neuroscientist and Stanford professor Dr. David Eagleman has teamed up with producers Matt Tauber and Adam ...

Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...